Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ALLO with free AI briefings, catalyst countdowns, and dilution alerts.

ALLO · Allogene Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$414.4M Cash on Hand
36.5mo Cash Runway
16.4% Short Interest
$9 Analyst Target (9)
Follow ALLO by email Get an email when ALLO reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ALLO, unsubscribe in one click. Privacy

📣 What ALLO Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Anti-CD52 Monoclonal Antibody ALLO-647 Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory… Phase 1/2 · NCT04416984 Active not recruiting
Fludarabine Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory… Phase 1/2 · NCT04416984 Active not recruiting

Also used in these trials (approved or third-party drugs, not ALLO's own candidates): Cyclophosphamide, Nirogacestat.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ALLO holds $414.4M in cash and short-term investments (as of Sep 30, 2026) and burns about $34.1M/quarter from operations, an estimated runway of 36.5 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 45 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ALLO files for a raise →

👥 Who Owns ALLO

Insiders 3.5% Other 5%+ holders 5.6% Institutions (275 holders) 81.5% Public and other holders 9.4%
HolderTypeShares% of sharesAs of
Kenneth Griffin Institution (13G, 5%+) 24,680,425 7.12% 2026-09-30
Citadel Advisors Llc Institution (13F) 24,558,325 7.09% 2026-09-30
BlackRock, Inc. Institution (13G, 5%+) 23,211,736 6.70% 2026-09-30
Frazier Life Sciences Management, L.P. Institution (13F) 22,446,668 6.48% 2026-09-30
Pfizer Inc. Institution (13G, 5%+) 22,032,040 6.36% 2025-11-06
Frazier Life Sciences Public Fund, L.P. 5%+ holder (13G) 19,445,046 5.61% 2026-06-30
State Street Corporation Institution (13F) 16,326,197 4.71% 2026-09-30
Primecap Management Company Institution (13F) 13,146,840 3.79% 2026-09-30
Vanguard Capital Management LLC Institution (13F) 12,050,271 3.48% 2026-09-30
UBS Group AG Institution (13F) 10,704,296 3.09% 2026-09-30
FMR, LLC Institution (13F) 10,599,559 3.06% 2026-09-30
Sio Capital Management, LLC Institution (13F) 9,104,151 2.63% 2026-09-30

Share count 346,467,307 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-10-21
filed 2026-10-23
Parker Geoffrey M.
Sale (S) 36,342 $1.34 1,045,877
2026-08-21
filed 2026-08-25
Douglas Earl Martin
Sale (S) 29,697 $2.12 488,267
2026-07-01
filed 2026-07-06
Roberts Zachary
Option award (A) 476,190 – –
2026-07-01
filed 2026-07-06
Roberts Zachary
Option award (A) 134,530 – –
2026-06-18
filed 2026-06-23
MESSEMER DEBORAH M.
Option award (A) 95,400 – –

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full ALLO picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ALLO and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.